Kuzmanovszki, D.; Kiss, N.; Tóth, B.; Kerner, T.; Tóth, V.; Szakonyi, J.; Lőrincz, K.; Hársing, J.; Imrédi, E.; Pfund, A.;
et al. Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study. Biomedicines 2022, 10, 1737.
https://doi.org/10.3390/biomedicines10071737
AMA Style
Kuzmanovszki D, Kiss N, Tóth B, Kerner T, Tóth V, Szakonyi J, Lőrincz K, Hársing J, Imrédi E, Pfund A,
et al. Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study. Biomedicines. 2022; 10(7):1737.
https://doi.org/10.3390/biomedicines10071737
Chicago/Turabian Style
Kuzmanovszki, Daniella, Norbert Kiss, Béla Tóth, Tünde Kerner, Veronika Tóth, József Szakonyi, Kende Lőrincz, Judit Hársing, Eleonóra Imrédi, Alexa Pfund,
and et al. 2022. "Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study" Biomedicines 10, no. 7: 1737.
https://doi.org/10.3390/biomedicines10071737
APA Style
Kuzmanovszki, D., Kiss, N., Tóth, B., Kerner, T., Tóth, V., Szakonyi, J., Lőrincz, K., Hársing, J., Imrédi, E., Pfund, A., Szabó, Á., Brodszky, V., Rencz, F., & Holló, P.
(2022). Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study. Biomedicines, 10(7), 1737.
https://doi.org/10.3390/biomedicines10071737
